[go: up one dir, main page]

WO2011085165A3 - Complexes immuns du ca-125 en tant que biomarqueurs du cancer ovarien - Google Patents

Complexes immuns du ca-125 en tant que biomarqueurs du cancer ovarien Download PDF

Info

Publication number
WO2011085165A3
WO2011085165A3 PCT/US2011/020465 US2011020465W WO2011085165A3 WO 2011085165 A3 WO2011085165 A3 WO 2011085165A3 US 2011020465 W US2011020465 W US 2011020465W WO 2011085165 A3 WO2011085165 A3 WO 2011085165A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune complexes
biomarkers
ovarian cancer
slides
plates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/020465
Other languages
English (en)
Other versions
WO2011085165A2 (fr
Inventor
Daniel Cramer
Brian Liu
Dennis O'rourke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to US13/520,665 priority Critical patent/US20120295814A1/en
Publication of WO2011085165A2 publication Critical patent/WO2011085165A2/fr
Publication of WO2011085165A3 publication Critical patent/WO2011085165A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a pour objet des dosages des complexes immuns du CA- 125 qui peuvent être utilisés de manière diagnostique. La présente invention concerne aussi des plaques ou des lames de verre ou de plastique sur lesquelles les anticorps monoclonaux contre le CA- 125 ont été immobilisés et des kits contenant ces plaques ou ces lames.
PCT/US2011/020465 2010-01-08 2011-01-07 Complexes immuns du ca-125 en tant que biomarqueurs du cancer ovarien Ceased WO2011085165A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/520,665 US20120295814A1 (en) 2010-01-08 2011-01-07 CA-125 Immune Complexes as Biomarkers of Ovarian Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29355110P 2010-01-08 2010-01-08
US61/293,551 2010-01-08

Publications (2)

Publication Number Publication Date
WO2011085165A2 WO2011085165A2 (fr) 2011-07-14
WO2011085165A3 true WO2011085165A3 (fr) 2011-11-24

Family

ID=44306159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020465 Ceased WO2011085165A2 (fr) 2010-01-08 2011-01-07 Complexes immuns du ca-125 en tant que biomarqueurs du cancer ovarien

Country Status (2)

Country Link
US (1) US20120295814A1 (fr)
WO (1) WO2011085165A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877795A4 (fr) * 2005-05-02 2010-04-28 Brigham & Womens Hospital Profilage diagnostique d'anticorps seriques
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (fr) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarqueurs de cancer ovarien
NZ627111A (en) 2008-11-26 2015-10-30 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
EP2758777B1 (fr) * 2011-09-22 2018-02-07 Memorial Sloan-Kettering Cancer Center Détection du cancer de l'ovaire
HK1218553A1 (zh) 2013-02-01 2017-02-24 Santa Maria Biotherapeutics, Inc. 抗激活素a化合物对受试者的施用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US20080286199A1 (en) * 2005-02-16 2008-11-20 Livingston David M Methods of Detecting Ovarian Cancer
US20090075305A1 (en) * 2005-05-02 2009-03-19 The Brigham And Womern's Hospital, Inc. Diagnostic serum antibody profiling
WO2009099561A2 (fr) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Peptides urinaires ca125 utilisés comme biomarqueurs du cancer de l’ovaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017410A1 (fr) * 1993-01-22 1994-08-04 Imre Corporation Dosage de complexe immun ameliore
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
CA2516591A1 (fr) * 2003-02-26 2004-09-10 Mount Sinai Hospital Dosage a marqueurs multiples utilise pour depister un cancer des ovaires
ITPD20030264A1 (it) * 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US20080286199A1 (en) * 2005-02-16 2008-11-20 Livingston David M Methods of Detecting Ovarian Cancer
US20090075305A1 (en) * 2005-05-02 2009-03-19 The Brigham And Womern's Hospital, Inc. Diagnostic serum antibody profiling
WO2009099561A2 (fr) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Peptides urinaires ca125 utilisés comme biomarqueurs du cancer de l’ovaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAYLOR, D. D. ET AL.: "Patient-derived tumor-reactive antibodies as diagnost ic markers for ovarian cancer", GYNECOL ONCOL., vol. 115, no. 1, 31 July 2009 (2009-07-31), pages 112 - 120, XP026541754, DOI: doi:10.1016/j.ygyno.2009.06.031 *

Also Published As

Publication number Publication date
US20120295814A1 (en) 2012-11-22
WO2011085165A2 (fr) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2011085165A3 (fr) Complexes immuns du ca-125 en tant que biomarqueurs du cancer ovarien
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
WO2015013388A3 (fr) Anticorps monoclonaux anti-galectine-1 et fragments de ces derniers
HK1207654A1 (en) Modified antibody regions and uses thereof
EP4461312A3 (fr) Anticorps anti-pro/myostatine latent et leurs utilisations
WO2010042562A3 (fr) Anticorps du muc1*
WO2014059442A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
HK1204981A1 (en) Antibodies to matrix metalloproteinase 9
WO2014165082A3 (fr) Anticorps et procédés de détection
EP3773716A4 (fr) Anticorps monoclonaux qui se lient à ssea4 et leurs utilisations
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
WO2009145815A3 (fr) Biomarqueurs de cancer ovarien
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
WO2015051320A3 (fr) Systèmes d'anticorps anti-sox10 et procédés associés
NZ611785A (en) Anti-notch1 antibodies
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
EP3672636A4 (fr) Procédés et compositions se rapportant à des réactifs d'anticorps anti-chi3l1
WO2018119425A3 (fr) Anticorps anti-lilrb3 et leurs procédés d'utilisation
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
WO2015006337A3 (fr) Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
WO2012154983A3 (fr) Systèmes et procédés pour des anticorps anti-pax8
EP4253959A3 (fr) Anticorps anti-idiotypiques dirigés contre la partie de liaison à l'antigène d'une molécule de liaison à bcma
WO2015075269A9 (fr) Anticorps dirigés contre ccr9 et leurs applications
EP3964525A4 (fr) Anticorps monoclonal se liant spécifiquement à gitr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11732183

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13520665

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11732183

Country of ref document: EP

Kind code of ref document: A2